Trump’s executive orders included overhauls to U.S. trade policy and declaring a national emergency at the southern border.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...

A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can have both health benefits and risks, including reduced risks of ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China.

Protein is highly satiating, helping you to feel more satisfied after eating than if you were to, say, have a bunch of carbs.

VANCOUVER, British Columbia and LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing mobile clinical network and ...